Skip to main content

Advertisement

Table 3 Summary of antitumor activity of HQP1351 in the treatment of GIST xenografts in nude mice

From: Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors

Model Drug Schedules Dose (mg/kg) RTV T/C (%)
GIST T1 Control    24.78 ± 2.51  
HQP1351 q3d × 2w 20 13.93 ± 3.26** 56.2
40 7.21 ± 1.05** 29.1
qw × 3w 20 17.13 ± 2.19 69.1
40 13.47 ± 2.17** 54.4
Ponatinib qw × 3w 40 16.10 ± 1.75* 65.0
GIST 430 Control q3d × 3w   6.38 ± 0.74  
HQP1351 q3d × 3w 10 3.58 ± 0.69** 56.1
50 2.39 ± 0.27** 37.5
Ponatinib q3d × 3w 50 2.80 ± 0.42** 43.9
  1. RTV relative tumor volume, calculated by dividing the absolute tumor volume at the end of experiment with the absolute tumor volume at day 1
  2. *P < 0.05 vs. control; **P < 0.01 vs. control